ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / WHWK / dividends
YARW (26) ZNTL (34) UPB (29) TRDA (16) ⌘ Pro Terminal β†’

Whitehawk Therapeutics Inc. (WHWK) Dividend Safety Gauge & 10-Year DRIP Compounder

$3.12 -3.70% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.09

Whitehawk Therapeutics Inc. (WHWK) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $184.7M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on WHWK Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is WHWK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Whitehawk Therapeutics Inc. (NASDAQ: WHWK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $3.12 (-3.70% 1D, market cap $184.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, WHWK ranks #938 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does WHWK compare to YARW and ZNTL in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), WHWK carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of 89.4%, and ROIC of -35.0%. By comparison, YARW (Yarrow Bioscience Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $185.2M) and ZNTL (Zentalis Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $185.6M). Among the 5-stock peer group, WHWK leads on earnings multiple (N/A) while WHWK leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for WHWK?
β–Ό

Per WHWK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001422142), Whitehawk Therapeutics Inc. generated $7.1M in revenue (-72.5% YoY), -$20.6M in net income, and -$98.0M in free cash flow against $150.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.09 (-0.86%)🧬 Dilution Drag (+1.28% YoY Shares)βš™οΈ Cash Engine: 4/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (24/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-10.9% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510024
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk E
Cash (4)Whales (4)SEC (7)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-15.4% Base Target
$6 Bull$3 Base$2 Bear
πŸ“¬ FREE WHWK RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for WHWK)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (24/100 Composite)
πŸ” WHY WHWK SCORES 24/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (29% of score)

Altman Z-Score 3.11 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 3/9

β–² #2 Bullish Driver: Macro Regime Fit+6/20 pts (25% of score)

FRED Regime Γ— Technicals: 33% of 52W Range β€’ RSI-14 at 42.9 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
32
Grade E$3.38-10.9% Next Q
Q2 (-2Q)
29
Grade E$3.01+4.3% Next Q
Q3 (-1Q)
27
Grade E$3.14-0.6% Next Q
Current
24
Grade E$3.12-10.9% Hist 90D Ξ±
Trajectory: E (32) β†’ E (24)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a WHWK Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While WHWK currently carries a cautious 24/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.83) and Max Pain ($3.28) forces dealer call-delta covering toward $5.76.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $WHWKβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œWHWK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 24%NO 76%Trade / Inspect Odds β†’
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 β€’ REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years β†’ $17,081

Est. Year-10 Shareholder Yield: $307/yr
$10.6K
Yr 1
$11.1K
Yr 2
$11.7K
Yr 3
$12.4K
Yr 4
$13.1K
Yr 5
$13.8K
Yr 6
$14.5K
Yr 7
$15.3K
Yr 8
$16.2K
Yr 9
$17.1K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring WHWK)

  • βœ“Walkthrough of WHWK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
WHWK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -25.00%β–Ό DESCENDING CHANNEL
2026-11-03O $3.30H $3.30L $3.12C $3.12VOL 153.4K
RES: $4.84SUP: $2.78SMA50: $3.83SMA200: $3.84
$5.69$4.86$4.02$3.19$2.35RES $4.84SUP $2.78$3.122026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

WHWK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ WHWK Butterfly Map β†’ + Track WHWK β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -72.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on WHWK today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for WHWK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for WHWK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (WHWK)

Health Care Rank #938 of 1015 βš”οΈ YARW vs WHWK Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (WHWK vs. YARW, ZNTL, UPB, TRDA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Whitehawk Therapeutics Inc. (WHWK) ranks #938 by composite RQD confidence (24/100, grade E) and #585 by equity capitalization ($184.7M). Within this direct 5-issuer industry benchmark cohort, WHWK leads on earnings valuation at N/A trailing P/E, while WHWK leads on capital efficiency and profitability with -35.0% ROIC and 89.4% gross margin. ZNTL currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with WHWK at 24/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
WHWK ACTIVE
Whitehawk Therapeutics Inc.
E 24/100 β€” 89.4% -35.0% -3.70% $184.7M Benchmark Subject
YARW
Yarrow Bioscience Inc.
E 26/100 β€” β€” -35.0% -9.90% $185.2M /yarw-vs-whwk β†’
ZNTL
Zentalis Pharmaceuticals Inc.
E 34/100 β€” β€” -35.0% -5.61% $185.6M /zntl-vs-whwk β†’
UPB
Upstream Bio Inc.
E 29/100 β€” β€” -35.0% -1.76% $186.8M /upb-vs-whwk β†’
TRDA
Entrada Therapeutics Inc.
E 16/100 β€” β€” -35.0% +12.68% $176.6M /trda-vs-whwk β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001422142 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Whitehawk Therapeutics Inc. (WHWK) reported GAAP revenue of $7.1M (-72.5% vs. FY2024 revenue of $26.0M , and -70.7% cumulative change since FY2023) , GAAP net income of -$20.6M, operating cash flow of -$97.4M, and free cash flow of -$98.0M (-60.1% YoY). On the balance sheet, WHWK closed FY2025 with $150.8M in total assets against $0 in total debt (Altman Z-Score: 3.11, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $7.1M -$20.6M -$97.4M -$98.0M $150.8M β€”
FY2024 (FY) 2024-12-31 $26.0M -$63.7M -$59.5M -$61.2M $70.3M β€”
FY2023 (FY) 2023-12-31 $24.4M -$65.8M -$59.7M -$59.7M β€” β€”

3. WHWK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is WHWK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Whitehawk Therapeutics Inc. (NASDAQ: WHWK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $3.12 (-3.70% 1D, market cap $184.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, WHWK ranks #938 in composite RQD confidence.

How does WHWK compare to YARW and ZNTL in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), WHWK carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of 89.4%, and ROIC of -35.0%. By comparison, YARW (Yarrow Bioscience Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $185.2M) and ZNTL (Zentalis Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $185.6M). Among the 5-stock peer group, WHWK leads on earnings multiple (N/A) while WHWK leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for WHWK?

Per WHWK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001422142), Whitehawk Therapeutics Inc. generated $7.1M in revenue (-72.5% YoY), -$20.6M in net income, and -$98.0M in free cash flow against $150.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is WHWK trading relative to its 50-day, 200-day, and 52-week technical levels?

WHWK last traded at $3.12 (-3.70% on volume of 216,121 shares), positioning the stock -18.54% below its 50-day simple moving average ($3.83) and -18.75% below its 200-day simple moving average ($3.84). Across its 52-week range of $1.97 to $5.49, WHWK sits at the 32.7% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($2.73 to $3.51).

Direct Sub-Reports: WHWK RQD Cockpit WHWK 12M Forecast WHWK Earnings & Move WHWK Dividends & DRIP WHWK Insiders & 13F WHWK Whale Options WHWK Profit Sankey WHWK News & Why
ROARABLE RATING BRIEF β€’ RQD 24/100 (E) βœ“ SEC XBRL & RQD VERIFIED

WHWK β€” Whitehawk Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Whitehawk Therapeutics Inc. (WHWK) earns a live Roarable RQD composite score of 24/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.12 (-3.70% 1D, market capitalization $184.7M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 89.4%, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of 3.11, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Whitehawk Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry. FY 2025 revenue was $7.1M, down from $26.0M in FY 2024.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Whitehawk Therapeutics Inc. (WHWK) reported $7.1M in annual revenue (up from $26.0M in FY2024, -72.5% YoY) and -$20.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($24.4M revenue, -$65.8M net income) through FY2025, WHWK scaled operating cash flow to -$97.4M and free cash flow to -$98.0M, backed by $150.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 24/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 4/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $1.97 – $5.49 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Supply_chain is NONE and butterfly_links is empty. The source data contains no upstream or downstream dependencies, sector correlation mapping, or bottleneck analysis. A prospective investor should note that the graph cannot identify second-order ripples from this data alone.

  • Key Question #1: Can WHWK sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $7.1M and free cash flow of -$98.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is WHWK's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

WHWK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Whitehawk Therapeutics Inc. (WHWK) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to WHWK Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

WHWK Bull vs. Bear Conversation Board β€” What's Your Call at $3.12?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON WHWK 🐻 33% BEARISH CONVICTION
1. Pick Your Side on WHWK:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER β€’ Options Flow Specialist πŸ‚ BULLISH 🎯 Target: $3.89 (+20.1%)
πŸ“Œ Pinned Debate

Per the market data, gross margin of 89.4% indicates high revenue-level economics if operating costs can be reduced.

Long WHWK at $3.24 targeting $3.89. Per the market data, gross margin of 89.4% indicates high revenue-level economics if operating costs can be reduced.. Institutional whale score is 4/20 and the risk/reward vs. the $1.97 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader πŸ‚ BULL

@RiskArb_Desk Shorting a 4/20 institutional whale-flow stock at $3.24 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER β€’ Hedged Event Driven 🐻 BEARISH 🎯 Target: $2.59 (-20.1%)
Spot @ $3.24

Per the SEC financials, free cash flow was negative in every reported period, with FY 2025 FCF at -$98.0M against $37.6M of cash.

I respect the product at Whitehawk Therapeutics Inc., but the stock at $3.24 is a different story. Per the SEC financials, free cash flow was negative in every reported period, with FY 2025 FCF at -$98.0M against $37.6M of cash.. FCF yield is 0.0% and RQD sits at 24/100 (E) β€” why pay up here when you can wait for next quarter's numbers?

LIVE TAPE